Cancer of the Esophagus Treatment Options

Treatment for esophageal cancer is not a single protocol but a layered strategy shaped by the cancer’s cell type, how far it has spread, where in the esophagus it sits, and a handful of molecular markers that increasingly guide drug selection. Options range from outpatient endoscopic procedures for very early tumors to complex combinations of chemotherapy, radiation, surgery, and immunotherapy for locally advanced or metastatic disease. The field has shifted substantially in recent years, with landmark trials reshaping the standard of care for both major subtypes of the disease.

Why the Cell Type Matters

Esophageal cancer comes in two main forms: squamous cell carcinoma, which arises from the flat cells lining most of the esophagus, and adenocarcinoma, which develops from glandular cells typically in the lower esophagus near the stomach. These two cancers behave differently, respond differently to treatment, and increasingly receive different treatment plans. Squamous cell carcinoma tends to be more sensitive to radiation, while adenocarcinoma often responds better to chemotherapy-heavy regimens.¹ In some regions of the world, particularly East Asia, squamous cell carcinoma dominates; in Europe and the United States, adenocarcinoma is more common.²

These differences are not academic. A large study found that squamous cell carcinoma patients were more likely to present at a lower stage and had higher rates of complete pathological response to chemoradiation than adenocarcinoma patients.³ The clinical and biological differences between the two types are significant enough that many oncologists now argue they should be treated as fundamentally distinct diseases.⁴

Endoscopic Treatment for Early-Stage Tumors

When esophageal cancer is caught very early, before it has grown deep into the esophageal wall or spread to lymph nodes, it can sometimes be removed without traditional surgery. Endoscopic submucosal dissection is a technique in which a specialist uses a flexible scope to peel away the cancerous tissue from the inside of the esophagus. It has high rates of complete tumor removal in one piece, and crucially, it preserves the esophagus.⁵ This matters enormously for quality of life because removing the esophagus surgically has major long-term effects on eating and digestion.

In countries with high rates of esophageal cancer, widespread screening catches more tumors at this early stage, which has driven the development of endoscopic techniques that achieve excellent results with minimal complications.⁶ For adenocarcinoma arising from Barrett’s esophagus, a precancerous condition linked to chronic acid reflux, radiofrequency ablation can destroy abnormal tissue before it progresses. Studies show this approach eliminates dysplasia in about 87% of patients and early cancer in roughly 80%.⁷

Chemotherapy and Radiation Before Surgery for Adenocarcinoma

For locally advanced esophageal adenocarcinoma, the standard approach involves treatment before surgery to shrink the tumor and improve the chances of a complete surgical removal. Two regimens have dominated: the CROSS protocol, which combines chemotherapy with radiation before surgery, and the FLOT protocol, which uses chemotherapy both before and after surgery without radiation. For years the two competed for supremacy, and the ESOPEC trial, published in the New England Journal of Medicine, appears to have settled the debate for adenocarcinoma.

The trial randomized patients with resectable adenocarcinoma to receive either FLOT or CROSS. At three years, about 57% of patients in the FLOT group were alive compared with about 51% in the CROSS group. Median survival was 66 months with FLOT versus 37 months with CROSS.⁸ Progression-free survival also favored FLOT. The investigators concluded that perioperative FLOT should be considered the new standard of care for resectable esophageal adenocarcinoma.⁹

That said, some experts have cautioned against applying the results too broadly. Not every patient fits neatly into the ESOPEC population, and ongoing discussion focuses on whether certain subgroups, particularly tumors at the gastroesophageal junction, might still benefit from radiation-based approaches.¹⁰

Treatment Decisions for Squamous Cell Carcinoma

The treatment picture for squamous cell carcinoma is different. Because this cancer type responds well to radiation, a real question exists about whether surgery is always necessary after chemoradiation. For patients who achieve a complete clinical response to chemoradiation, some researchers have asked whether adding surgery improves outcomes or simply adds risk.

The evidence leans toward surgery remaining important, but with nuances. A large observational analysis found that patients who received chemoradiation followed by surgery had a three-year survival rate of about 41%, compared with roughly 18% for those treated with chemoradiation alone. That gap was significant and held across both stage II and stage III disease.¹¹ Another study echoed this, concluding that surgery reduces local recurrence and should remain part of the standard approach until better tools exist to identify which patients truly had a complete response.¹²

However, a phase II randomized trial specifically enrolled squamous cell carcinoma patients who achieved a complete clinical response after initial chemoradiation and then randomized them to surgery or continued chemoradiation alone. The three-year overall survival rates were comparable at about 70% and 62%, without a statistically significant difference.¹³ This suggests that for the subset of patients who clearly respond completely, skipping surgery might be reasonable, but the trial was small, and larger confirmatory studies are needed. For now, most guidelines continue to recommend surgery for patients who are fit enough.

How Esophageal Surgery Has Changed

Esophagectomy, the surgical removal of part or all of the esophagus, remains one of the most complex operations in cancer surgery. Over the past few decades, outcomes have improved dramatically thanks to earlier diagnosis, better patient selection, enhanced recovery protocols, and the shift from fully open operations to minimally invasive and robotic techniques.¹⁴

Robot-assisted minimally invasive esophagectomy is now established at high-volume centers. Compared with open surgery, robotic approaches have been linked to fewer pulmonary complications, fewer cardiovascular complications, and fewer wound infections, despite taking somewhat longer in the operating room.¹⁵ The ROBOT trial, a randomized comparison, found that surgery-related complications dropped from 59% with open surgery to 47% with robotic surgery, with particularly large reductions in lung and heart complications.¹⁶

One ongoing debate in surgery is how many lymph nodes to remove. A randomized trial comparing three-field lymph node removal (neck, chest, and abdomen) with two-field removal (chest and abdomen) found that five-year survival was identical at 63% in both groups.¹⁷ But a meta-analysis of multiple studies found that three-field dissection improved one-, three-, and five-year survival rates at the cost of more complications, particularly nerve damage affecting the voice and a higher rate of anastomotic leak.¹⁸ The conflicting results mean the extent of lymph node dissection is still tailored to each patient and varies by institution.

Immunotherapy’s Growing Role

Immunotherapy has become a cornerstone of esophageal cancer treatment at multiple stages of the disease. After surgery, the CheckMate 577 trial demonstrated that nivolumab roughly doubled the time before cancer returned. Patients who received nivolumab had a median disease-free survival of about 22 months, compared with 11 months for those on placebo.¹⁹ This benefit was most pronounced in patients whose tumors had residual disease after chemoradiation and surgery, making adjuvant nivolumab standard for many patients who have undergone the CROSS regimen. A cost-effectiveness analysis estimated that this approach adds roughly one additional year of survival, primarily in a disease-free state.²⁰

For advanced or metastatic esophageal cancer, the KEYNOTE-590 trial established pembrolizumab combined with chemotherapy as a first-line treatment. Five-year follow-up data showed that adding pembrolizumab extended median overall survival from about 10 months to about 12 months. While that sounds modest, the five-year survival rate told a starker story: roughly 11% of patients receiving pembrolizumab plus chemotherapy were alive at five years compared with 3% receiving chemotherapy alone.²¹ The benefit was particularly strong in patients whose tumors expressed high levels of PD-L1.²²

Targeted Drugs and Biomarker Testing

Beyond immunotherapy, a growing menu of targeted drugs is available for esophageal and gastroesophageal junction cancers, but they only work when the tumor carries the right molecular target. HER2-positive tumors, which account for a meaningful minority of adenocarcinomas, have been treated with trastuzumab since the ToGA trial showed improved survival when it was added to chemotherapy.²³ For patients whose HER2-positive tumors progress on initial therapy, trastuzumab deruxtecan, an antibody-drug conjugate, has shown a response rate of about 51% compared with 14% for standard chemotherapy, with median survival extending from roughly 8 months to about 12.5 months.²⁴

A newer target is a protein called claudin 18.2, found on the surface of some gastric and gastroesophageal junction adenocarcinomas. Zolbetuximab, an antibody directed at this protein, improved both progression-free survival and overall survival when added to chemotherapy in two phase III trials for HER2-negative tumors that express claudin 18.2.²⁵ These advances mean that molecular profiling of the tumor is now standard practice, because it directly determines which drugs a patient can receive.

Proton Therapy and Radiation Advances

Radiation remains central to esophageal cancer treatment, whether used before surgery, as part of definitive therapy, or for palliation. Proton beam therapy has emerged as an alternative to conventional photon radiation because it deposits energy more precisely, sparing the heart and lungs from excess dose.²⁶

A randomized trial comparing proton therapy with intensity-modulated radiation therapy for locally advanced esophageal cancer found that the total burden of side effects was more than twice as high with conventional radiation. The severity of complications involving the heart, lungs, and surgical wound was about seven times greater with conventional photon therapy. Survival and progression-free survival were identical between the two approaches.²⁷ A meta-analysis confirmed that proton therapy significantly reduced the odds of moderate or worse lung inflammation compared with photon therapy.²⁸ The practical barrier is availability: proton therapy centers are still far less common than standard radiation facilities.

Managing Symptoms When Cure Is Not the Goal

For patients with metastatic esophageal cancer, difficulty swallowing is often the most distressing symptom. The two main options for relieving it are placing a metal stent to hold the esophagus open or delivering palliative radiation. A large study found that stents carried a higher rate of serious complications at six months, including fistula, perforation, and bleeding. Radiation provided equally good relief of swallowing difficulty over time and was also better at controlling pain.²⁹ Stents offer faster initial relief but tend to cause more problems down the line, which makes the choice depend partly on how quickly symptoms need to improve and the patient’s overall prognosis.

Life After Esophagectomy

Recovery from esophageal surgery is a long road. Nutritional support is one of the earliest and most critical challenges. Evidence favors feeding through the gut, via a tube placed directly into the small intestine, over intravenous nutrition. Gut feeding is associated with fewer complications and faster recovery. Some patients can start eating by mouth soon after surgery, but there is evidence that very early oral feeding may increase the risk of anastomotic leaks, the separation of surgical connections inside the body.³⁰

Swallowing difficulty persists long after surgery. Even patients who do not develop obvious complications like nerve damage or scar tissue at the surgical join show mild to moderate swallowing problems years later, and the rate of aspiration, where food or liquid enters the airway, remains comparable to what is seen in the early postoperative period.³¹ Overall quality of life, measured at least a year after surgery, remains significantly lower than the general population’s, and the degree of swallowing difficulty is strongly linked to how poor that quality of life feels.³² These findings underscore why endoscopic treatments for early cancers are so valued when they are an option, and why rehabilitation and dietitian support are not optional extras after surgery.

Getting Fit Before Treatment

Prehabilitation, the practice of building up a patient’s physical fitness before major surgery, has gained traction in esophageal cancer care. A study of patients who developed postoperative complications found that those who participated in a prehabilitation program had a significantly shorter hospital stay than those who did not.³³ Programs typically involve supervised exercise, nutritional optimization, and psychological support. Emerging evidence suggests that prehabilitation is safe and measurably improves patients’ physical capacity heading into treatment.³⁴ For a disease where the treatment itself carries serious risks, arriving at the operating table in the best possible shape can make a real difference in how the recovery unfolds.

Antibody-Drug Conjugates and the Next Wave

Treatment resistance remains one of the biggest obstacles in esophageal cancer. When tumors stop responding to standard chemotherapy and immunotherapy, options become limited. The mechanisms behind resistance are complex, involving the tumor’s surrounding environment, changes in how cancer cells metabolize energy, and the persistence of treatment-resistant stem-like cancer cells.³⁵

Antibody-drug conjugates represent one of the most promising new approaches. These drugs use an antibody to find and latch onto cancer cells, then deliver a potent chemotherapy payload directly inside the cell. One bispecific antibody-drug conjugate called BL-B01D1, which targets two proteins on the cell surface simultaneously, has shown compelling early results in squamous cell carcinoma that has stopped responding to immunotherapy.³⁶ A global phase III trial is also underway testing ifinatamab deruxtecan, which targets the B7-H3 protein, in advanced squamous cell carcinoma that has progressed after platinum-based chemotherapy and checkpoint inhibitors. These drugs are designed precisely for the clinical situation where current treatments have failed, and results from these trials could reshape the treatment landscape for relapsed esophageal cancer within the next few years.